Microcap Ledger MiNK Therapeutics, Inc. $INKT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 5,103,002 [10-Q 2026-08-13]
What the company doesAI summary of filing
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf cell therapies using invariant natural killer T (iNKT) cells to treat cancer and immune-mediated diseases. The company's lead product candidate, agenT-797, is a native iNKT cell therapy currently in Phase 1/2 clinical trials across multiple indications including solid tumor cancers, critical pulmonary immune failure, and graft-versus-host disease, with no revenue generated to date. MiNK also has a pipeline of engineered iNKT cell therapies in preclinical development, including CAR-iNKT programs and bispecific engagers, supported by proprietary manufacturing capabilities and collaborations with other companies for combination therapies. The company generates no revenue and operates as a pre-revenue, development-stage entity. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$5.87M | −$3.82M | $8.81M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$12.49M | −$5.93M | $13.36M | [10-K 2026-03-31] |
| FY ended Dec 2024 | — | −$10.78M | −$9.56M | $4.58M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$1.91M
- Cash runway Estimate
- ~13.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 39,549,975 | [10-Q 2024-11-14] |
| 2025-03-13 | 3,966,392 | [10-K 2025-03-18] |
| 2025-05-12 | 3,985,657 | [10-Q 2025-05-15] |
| 2025-08-12 | 4,522,927 | [10-Q 2025-08-14] |
| 2025-11-13 | 4,694,155 | [10-Q 2025-11-14] |
| 2026-03-27 | 4,965,858 | [10-K 2026-03-31] |
| 2026-05-13 | 4,981,899 | [10-Q 2026-05-15] |
| 2026-08-11 | 5,103,002 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2025-11-07; declared effective 2025-12-11 [S-3 2025-11-07]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-01 | Wiinberg Ulf | grant | 1,279 | $10.95 | [4 2026-09-02] |
| 2026-09-01 | Holcomb John Bradley | grant | 1,233 | $10.95 | [4 2026-09-02] |
| 2026-09-01 | Behner Peter | grant | 1,485 | $10.95 | [4 2026-09-02] |
| 2026-09-01 | Ryan Barbara | grant | 1,622 | $10.95 | [4 2026-09-02] |
| 2026-09-01 | Corvese Brian | grant | 1,633 | $10.95 | [4 2026-09-02] |
| 2026-06-04 | Ryan Barbara | sell | 500 | $12.68 | [4 2026-06-05] |
| 2026-06-04 | Ryan Barbara | sell | 1,000 | $12.80 | [4 2026-06-05] |
| 2026-06-01 | Holcomb John Bradley | grant | 1,091 | $12.38 | [4 2026-06-02] |
| 2026-06-01 | Ryan Barbara | grant | 1,434 | $12.38 | [4 2026-06-02] |
| 2026-03-02 | Holcomb John Bradley | grant | 1,239 | $10.90 | [4 2026-06-02] |
| 2026-03-02 | Ryan Barbara | grant | 1,629 | $10.90 | [4 2026-06-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-06-23 | 8-K | Shareholder vote results |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-15 | 8-K | Results of operations |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-03-31 | 10-K | Annual report |
| 2026-03-31 | 8-K | Results of operations |
| 2026-03-27 | 8-K | Other events |
| 2026-03-19 | 8-K | Director or officer change |
| 2026-01-02 | 8-K | Director or officer change |
| 2025-12-10 | S-3/A | Registration statement |
Alerts for $INKT
Email me when MiNK Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.